Chiesi Group Partners with Aliada Therapeutics to Advance Blood-Brain Barrier Technology for Rare Diseases

Chiesi Group has entered an exclusive licensing agreement with Aliada Therapeutics, a subsidiary of AbbVie, to develop therapies that can cross the blood-brain barrier (BBB) for lysosomal storage disorders (LSDs).…

Continue Reading Chiesi Group Partners with Aliada Therapeutics to Advance Blood-Brain Barrier Technology for Rare Diseases

Jim Wilson’s Pioneering Journey: Transforming Rare Disease Treatment Through Innovative Gene Therapy Part 2

Please go HERE to read Part 1 of this article The company, GEMMABIO, will pursue a number of rare, large indications.  A new spinout, RareTx, will be dedicated to Orphan…

Continue Reading Jim Wilson’s Pioneering Journey: Transforming Rare Disease Treatment Through Innovative Gene Therapy Part 2

Breakthrough FDA Approval Offers First-Ever Treatment for Life-Threatening Mitochondrial Energy Disorder

The U.S. Food and Drug Administration has approved UCB's Kygevvi, marking a historic milestone for patients with thymidine kinase 2 deficiency (TK2d), an ultra-rare inherited mitochondrial disorder that has lacked…

Continue Reading Breakthrough FDA Approval Offers First-Ever Treatment for Life-Threatening Mitochondrial Energy Disorder

Jim Wilson’s Pioneering Journey: Transforming Rare Disease Treatment Through Innovative Gene Therapy Part 1

As noted in a recent article published in Inside Precision Medicine, in 1992 gene therapy was often discussed but seldom practiced.  When Jim Wilson MD, PhD attended Penn State, gene…

Continue Reading Jim Wilson’s Pioneering Journey: Transforming Rare Disease Treatment Through Innovative Gene Therapy Part 1